摘要
目的:探讨利伐沙班用于非瓣膜性心房颤动患者抗凝治疗的疗效及安全性。方法:回顾性选取2017年1月至2018年4月东莞市人民医院收治的非瓣膜性心房颤动患者120例,根据给药方案分为A组和B组,每组60例。A组患者采用华法林治疗,B组患者采用利伐沙班治疗。观察两组患者的临床疗效、不良事件发生情况。结果:B组患者的总有效率为98.33%(59/60),明显高于A组的86.67%(52/60),差异有统计学意义(P<0.05);B组患者不良事件发生率为6.67%(4/60),明显低于A组的16.67%(10/60),差异有统计学意义(P<0.05)。结论:利伐沙班可提高非瓣膜性心房颤动患者抗凝治疗的临床疗效,降低不良事件的发生率,安全性高。
OBJECTIVE: To probe into the efficacy and safety of rivaroxaban in anticoagulant treatment of patients with non-valvular atrial fibrillation(NVAF). METHODS: 120 patients with NVAF admitted into Dongguan People’s Hospital from Jan. 2017 to Apr. 2018 were retrospectively selected and divided into group A and group B according to different administration regimens, with 60 cases in each group. Group A was treated with warfarin, while group B was given rivaroxaban. Clinical efficacy and incidences of adverse drug reactions of two groups were compared. RESULTS: The total effective rate of group B was 98.33%(59/60), which was significantly higher than that of group A(86.67%, 52/60), with statistically significant difference(P<0.05);the incidence of adverse drug reactions of group B was 6.67%(4/60), which was significantly lower than that of group A(16.67%, 10/60), with statistically significant difference(P<0.05). CONCLUSIONS: Rivaroxaban can improve the efficacy of anticoagulant treatment on patients with NVAF, which can reduce the incidence of adverse drug reactions, with high safety.
作者
江丽华
黄嘉利
陈丽华
JIANG Lihua;HUANG Jiali;CHEN Lihua(Office of Drug Clinical Trials Agency,Dongguan People’s Hospital,Guangdong Dongguan 523000,China;Dept.of Cardiovascular Medicine,Dongguan People’s Hospital,Guangdong Dongguan 523000,China)
出处
《中国医院用药评价与分析》
2019年第3期304-305,308,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
